This phase II/III trial is comparing two intravenous drugs (Irinotecan liposome injection and Topotecan injection) in patients with small cell lung cancer who have gotten worse after first line therapy.
This trial is treating patients with small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Commercial Sponsor
Ipsen
Summary
This trial contains two parts - a dose finding study of irinotecan liposome injection and a randomised efficacy study comparing irinotecan liposome injection and intravenous topotecan.
Recruiting Hospitals Read More